Big Pharma’s $300B Patent Cliff Spurs Biotech Buyouts

Major drugmakers are increasing purchases of smaller biotech companies as more than $300 billion in branded drug revenue is scheduled to lose patent protection by the end of the decade. AbbVie’s $10.9 billion cash acquisition of Apogee Therapeutics is one recent example of that trend.

PwC’s midyear deals outlook estimates over $300 billion in branded pharmaceutical revenue will face loss of exclusivity through 2030. Companies facing those expiring patents are obtaining late-stage clinical assets from outside developers rather than relying solely on internal drug development programs.

Deal activity has shifted toward mid-size, bolt-on acquisitions that involve specialist developers and late-stage candidates. PitchBook data cited by industry advisers indicates total biopharma deal value is on pace to exceed $250 billion in 2026, a level not seen since 2019. Analysts say such bolt-on purchases typically draw less regulatory scrutiny than large, integrated mergers.

The ALPS Medical Breakthroughs ETF, known as SBIO, tracks U.S. biotech companies with market caps between $200 million and $5 billion that have at least one drug in Phase II or Phase III trials and hold roughly two years of cash to continue operations. SBIO’s semiannual rebalance on June 18 added 37 companies and removed 15, reflecting turnover among firms at this development stage.

One company added to the fund, Definium Therapeutics, released trial results shortly after the rebalance that sent its shares up more than 90 percent. Instead of accepting an acquisition offer, Definium completed an upsized $700 million equity raise to fund a regulatory submission and potential approval efforts.

Regulatory updates have also affected company plans. On June 17 the U.S. Food and Drug Administration signaled a more flexible approval pathway for therapies targeting serious and rare diseases. Industry advisers say the change could speed filings for some products and make smaller developers with near-term approval candidates more attractive acquisition targets for large drugmakers.

Large pharmaceutical companies are using acquisitions of late-stage assets to add near-term commercial candidates while older branded products lose market protection and face generic competition. The strategy involves deploying significant capital to secure drugs that can be commercialized as patent-protected revenues decline.

Institutional investors and fund managers have adjusted allocations toward smaller biotech firms where buyout activity and trial readouts can drive rapid valuation changes. Recent ETF performance and deal announcements reflect increased activity in the midcap biotech segment. Data on deal volumes and corporate filings indicate heightened transaction activity is likely to continue through 2026 as companies address the revenue at risk from expiring patents.